Discoveries in Microbiology and Immunology Drive the Markets and Ensure A Bright and Healthy Future
SINGAPORE and LONDON (PRWEB) October 30, 2018 -- Omics International celebrated the 10th International Open Access Week from 22nd October to the 28th October, 2018. This year’s theme- “designing equitable foundations for open knowledge,” was an attempt at evaluating the open access policies and practices implemented by governments, universities, publishers, funders, and scholars.
Simultaneously, it aimed to identify the bottlenecks and the misdirections en route to a completely ‘open-access world,’ patent trolls being a case in point. When research becomes freely accessible to the wider public, some of it falls within the grasp of patent trolls- companies that have no purpose other than amassing patents and suing innovators who created similar inventions, independently; thereby, imposing an extensive burden on innovation.
Microbiology and Immunology is a scientific domain that is host to prolific innovations, and also happens to rank among some of the most energetic and innovative markets. The microbiology market is being propelled forward by: the identification of new microbial strains; increased preference of the end-users for consumer products, such as nutraceuticals, food items, packaged water, and OTC drugs; the growing demand for pathogen testing in food items; technological innovations in infectious disease testing; increase in outbreaks of infectious disease; increasing automation; rising collaboration among pharmaceutical companies; and growing research initiatives in various fields of microbiology.
On the other hand, the global immunology market is host to a number of blockbuster drugs, such as Humira, Remicade, Rituxan, Simponi, and Cimzia, all of which are monoclonal antibodies. New drugs, such as Cosentyx, Otezla, AR-101, Filgotinib, and Upadacitinib tartrate are expected to generate an additional thrust within the immunology market. These blockbuster drugs are going to propel the global immunology drugs market to $113 billion by 2023, at a compound annual growth rate (CAGR) of more than 8%, with the United States accounting for nearly half of this market.
In the last 30 years, journal subscription fees have outpaced inflation by 250%. The open access movement would allow innovators in the prolific field of Microbiology and Immunology to leverage and build upon the latest scientific research, regardless of whether their budgets allow for access to expensive journal subscriptions- particularly when that research was conducted using public funds. Furthermore, open access allows small businesses and entrepreneurs to be more innovative, thereby stimulating regional economies. It also encourages collaborations and increases the returns on financial investments.
Omics journals have a significant footprint in the field of microbiology and immunology, with leading journals like Journal of Microbial & Biochemical Technology, Journal of Bioremediation & Biodegradation, Journal of Clinical & Cellular Immunology, Journal of Medical Microbiology & Diagnosis, and Journal of AIDS & Clinical Research Publishing figuring prominently on its portfolio.Dr. Srinubabu Gedela, the Founder and CEO of Omics International had started Omics with the intention of making healthcare and scientific information accessible to all. Though the initial enthusiasm for open access publishing was tempered by the fear of ‘negative connotations,’ stemming from criticism regarding peer-review and credibility, now more and more researchers are embracing the open access movement with gusto.
During the Open Access Week, Omics renewed its commitment to the open access philosophy. Dr. Gedela had announced special recognition for manuscripts submitted in this duration.
All the authors, Editors made their own personal contribution to the Open Access movement by sharing their views on the movement and giving their inputs on shaping the open access policies for a more equitable future.
Established in the year 2007, Omics publishes 700+ open access journals in the fields of clinical, medical, and pharmaceutical in addition to engineering and managerial science. All the journals follow a structured peer-review process with the support of its 50,000+ editorial board members and peer-reviewers. The journals gained wide popularity which is evident from the fact that the readership/viewership increased from 10,000 in 2009 to 25 million in 2017.
Abhishek Babu, PULSUS GROUP, http://www.pulsus.com, +91 4047482201, [email protected]
Share this article